X0306 4 2018-05-23 0 0001571949 Intercontinental Exchange, Inc. ICE 0001343882 Sprecher Jeffrey C 5660 NEW NORTHSIDE DRIVE ATLANTA GA 30328 1 1 0 0 Chief Executive Officer Common Stock 2018-05-23 4 M 0 86000 21.20 A 1598138 D Common Stock 2018-05-23 4 M 0 4430 25.87 A 1602568 D Common Stock 2018-05-23 4 S 0 122989 70.9483 D 1479579 D Common Stock 2018-05-23 4 M 0 8375 22.43 A 123099 I By spouse Common Stock 2018-05-23 4 S 0 12269 70.9501 D 110830 I By spouse Employee Stock Option (right to buy) Holding 21.20 2018-05-23 4 M 0 86000 0.00 D 2019-12-10 Common Stock 86000 0 D Employee Stock Option (right to buy) Holding 25.87 2018-05-23 4 M 0 4430 0.00 D 2023-01-11 Common Stock 4430 157745 D Employee Stock Option (right to buy) Holding 22.43 2018-05-23 4 M 0 8375 0.00 D 2022-01-17 Common Stock 8375 0 I By spouse The transactions reported in this Form 4 were effected pursuant to a previously announced, pre-arranged trading plan established in accordance with Rule 10b5-1 of the Securities Act of 1934, as amended. The price range for the aggregate amount sold by the direct holder is $70.49 - $71.47. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. The common stock number referred in Table I is an aggregate number and represents 1,365,535 shares of common stock and 114,044 unvested performance based restricted stock units, for which the performance period has been satisfied. These performance based restricted stock units vest over a three year period, in which 33.33% of the units vest each year. The satisfaction of the 2018 performance based restricted units tied to earnings before interest, taxes, depreciation, and amortization, ("EBITDA") and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2019 and will be reported at the time of vesting. The satisfaction of the 2017 and 2018 total shareholder return performance based restricted stock units and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2020 and February 2021, respectively, and will be reported at the time of vesting. As previously reported, the reporting person also indirectly owns 3,791,705 shares that are beneficially owned directly by CPEX. The reporting person beneficially owns 100% of the equity interest in CPEX. Additionally, as previously reported, the reporting person indirectly owns shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership. The price range for the aggregate amount sold by the direct holder is $70.52 - $71.44. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. The common stock number referred in Table I is an aggregate number and represents 99,670 shares of common stock and 11,160 unvested performance based restricted stock units, for which the performance period has been satisfied. These performance based restricted stock units vest over a three year period, in which 33.33% of the units vest each year. The satisfaction of the 2018 performance based restricted units tied to earnings before interest, taxes, depreciation, and amortization, ("EBITDA") and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2019 and will be reported at the time of vesting. The satisfaction of the 2017 and 2018 total shareholder return performance based restricted stock units and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2020 and February 2021, respectively, and will be reported at the time of vesting. As previously reported, the reporting person also indirectly owns 3,791,705 shares that are beneficially owned directly by CPEX. The reporting person beneficially owns 100% of the equity interest in CPEX. Additionally, as previously reported, the reporting person also beneficially owns shares directly. These options are fully vested. /s/ Andrew J. Surdykowski, Attorney-in-fact 2018-05-25